1. Home
  2. PCRX vs MAX Comparison

PCRX vs MAX Comparison

Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$23.19

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$9.75

Market Cap

516.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
MAX
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
516.4M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
PCRX
MAX
Price
$23.19
$9.75
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
$37.20
$12.70
AVG Volume (30 Days)
573.7K
521.8K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
25.81
EPS
0.16
0.39
Revenue
$541,533,000.00
$1,113,600,000.00
Revenue This Year
$6.78
$13.42
Revenue Next Year
$8.54
$8.16
P/E Ratio
$140.69
$24.49
Revenue Growth
26.04
28.78
52 Week Low
$18.80
$7.09
52 Week High
$27.99
$13.92

Technical Indicators

Market Signals
Indicator
PCRX
MAX
Relative Strength Index (RSI) 54.40 54.12
Support Level $22.57 $9.31
Resistance Level $23.94 $11.10
Average True Range (ATR) 0.77 0.39
MACD -0.03 0.01
Stochastic Oscillator 61.42 84.98

Price Performance

Historical Comparison
PCRX
MAX

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

Share on Social Networks: